Ruby Grewal

Ruby Grewal currently serves as an Executive in Residence at Roivant Sciences, a position held since August 2023. Prior to this role, Ruby held the position of Chief Strategy Officer at Proteovant Therapeutics from May 2021 to August 2023. Ruby has extensive experience at Roivant Sciences, holding roles as VP Governance from 2020 to May 2021 and VP Business Development from 2016 to 2019. Earlier in the career, Ruby worked as a Portfolio Manager and HC Investor at Straus Asset Management and Greywall Asset Management from 2002 to 2015. Ruby earned a Bachelor of Science in Engineering in Biomedical/Medical Engineering and an MBA from Duke University and The Fuqua School of Business, respectively.